Piramal Pharma Solutions, the contract development and manufacturing division of Piramal Pharma Ltd, is investing USD 80 million (around INR 670 crore) to expand its Lexington facility. The expansion, set for completion by early 2027, will add 24,000 square feet of manufacturing space, advanced machinery, and a new laboratory. This will more than double production capacity from 104 to over 240 batches annually and create 40 new jobs. The facility focuses on sterile injectable drugs, supporting the company's antibody-drug-conjugate program. With the injectables market projected to surpass USD 20 billion by 2028, the expansion positions Piramal for significant growth.
Piramal Pharma Solutions, the contract development and manufacturing division of Piramal Pharma Ltd (PPL), has announced an ambitious USD 80 million (approximately INR 670 crore) investment to expand its Lexington facility. This expansion will add 24,000 square feet of manufacturing space, a new laboratory, and advanced machinery aimed at scaling client products efficiently. Key upgrades include a new filling line, two commercial-size lyophilizers, a specialized capping machine, and an external vial washer.
Currently, the Lexington site can produce 104 product batches annually at peak utilization. Upon completion of the expansion in the first quarter of 2027, this capacity will more than double to over 240 batches per year, while also creating 40 new full-time jobs. The facility focuses on sterile compounding, liquid filling, and lyophilisation for sterile injectable drug products, playing a pivotal role in Piramal's integrated antibody-drug-conjugate development program, ADCelerate. Several clients have already committed to commercializing their products at the expanded Lexington site.
The expansion, funded through bank loans and internal resources, aims to enhance the facility's capabilities to cater to a growing market. Nandini Piramal, Chairperson of PPL, highlighted that addressing the commercial manufacturing gap positions the Lexington site as a key player in the rapidly expanding injectables market. With significant research and development driving growth in this sector, the injectables market is projected to exceed USD 20 billion by 2028, underscoring the need for robust commercial-scale manufacturing capabilities.
This expansion represents a strategic move for Piramal Pharma Solutions to strengthen its foothold in the injectables market. By enhancing its manufacturing capabilities, the company is well-positioned to meet the increasing demands of a rapidly evolving industry.
Advertisement
Facebook
Whatsapp
